Although I realize the point of Bill Mann's article was not to discuss Hemispherx Biopharma, per se, that the larger point of it was to show that people are still easily swayed by so-called analyst coverage, I was intrigued by the dubiousness of their press release regarding the "royal family" and did a Google search of the company.Interestingly, it appears the company has run afoul of the FDA a couple of times in the past for its press releases, website and promotional materials. Here's a letter the FDA sent to the company back in July, 2000, admonishing them for promoting their drug Ampligen:http://www.pharmcast.com/WarningLetters/July2000/Hemispherx0700.htmIt notes, "We previously issued an untitled letter, dated October 15, 1998, to Hemisphcrx for promoting Ampligen as safe or effective while the product was under investigation....However, notwithstanding your assurances, you continue to promote Ampligen as safe and effective prior to approval in your press releases and on your Internet website."I looked around their website briefly but did not find any Ampligen "promotion," but I did notice that the Taglich report was laden with it. And as the Hemispherx pays the company a monthly fee to produce such reports, I wonder if that's not coming awfully close to flouting the FDA's directive...again!Thanks, Bill, for pointing out this egregious case study.Rich
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra